Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy

Activated B-cells are a promising alternative source of antigen-presenting cells. They can generally be obtained in sufficient numbers for clinical use, but in most instances produce weak immune responses and therapeutic effects that are suboptimal for use in therapeutic cancer vaccines. To improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Chang-Ae, Cho, Hyun-Woo, Shin, A-Ri, Sohn, Hyun-Jung, Cho, Hyun-Il, Kim, Tai-Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216789/
https://www.ncbi.nlm.nih.gov/pubmed/27323820
http://dx.doi.org/10.18632/oncotarget.10068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216789/
https://www.ncbi.nlm.nih.gov/pubmed/27323820
http://dx.doi.org/10.18632/oncotarget.10068

Ejemplares similares